INCY Stock Recent News
INCY LATEST HEADLINES
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Data for Incyte's TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and Selective Inhibitor of G12D-mutated KRAS (INCB161734) Accepted at ESMO 2025.
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 1375458.
Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with Jakafi delivering $709M in Q1 2025 and strong growth across indications. Q1 2025 revenue grew 20% year-over-year to $1.05B, prompting management to raise full-year guidance, reflecting confidence in core products.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).